JEFFREY J. TARRAND, M.D.
Medical Practice at Holcombe Blvd, Houston, TX
License number
Texas H5137
Category
Medical Practice
Type
Clinical Pathology/Laboratory Medicine
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about JEFFREY J. TARRAND at radaris.comName
Address
Phone
4706 Braesvalley Dr, Houston, TX 77096
Professional information
Large Animal Model Of Invasive Pulmonary Aspergillosis In An Immunocompromised Host
US Patent:
6444872, Sep 3, 2002
Filed:
Aug 18, 2000
Appl. No.:
09/642397
Inventors:
Borje S. Andersson - Houston TX
Taraneh K. Sadeghi - Houston TX
Douglas M. Cromeens - Spring TX
Jeffrey J. Tarrand - Houston TX
Taraneh K. Sadeghi - Houston TX
Douglas M. Cromeens - Spring TX
Jeffrey J. Tarrand - Houston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A01K 6700
US Classification:
800 11, 800 14, 424423, 435 4, 435 72, 435 731
Abstract:
A model of systemic mold/Aspergillus infection in a profoundly immunocompromised host has been established in the beagle dog. The beagle was rendered immunosuppressed using a combination of total body irradiation and daily steroids, which provided a window of time where the mold could be successfully inoculated through a bronchoscope. This created a localized infection in one lung lobe, which subsequently spread diffusely throughout the lung parenchyma, and uniformly resulted in the animals death. The invention contemplates the further study of the pathophysiology of opportunistic mold infections in vivo and also provides examples for the development of new antifungal agents and more effective combinations of agents. Finally, the invention contemplates the development of technology for the early detection of systemic mold infections. The inventors envision, that the use of the model should help save patients from clinical trials of antifungal drugs that may be effective in vitro without living up to the expectations in a clinical setting.
Dr. Jeffrey J Tarrand, Rochester MI - MD (Doctor of Medicine)
Specialties:
Clinical Pathology
Address:
380 Sussex Fair, Rochester 48309
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
Certifications:
Clinical Pathology, 1990
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
380 Sussex Fair, Rochester 48309
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Education:
Medical School
University of Virginia / Main Campus
Graduated: 1981
University Of Virginia Medical Center
Washington University
University of Virginia / Main Campus
Graduated: 1981
University Of Virginia Medical Center
Washington University
Jeffrey James Tarrand, Houston TX
Specialties:
Pathology, Clinical Pathology/Laboratory Medicine, Clinical Pathology
Work:
M D Anderson Cancer Ctr
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
University of Virginia (1981)
Parenteral Formulations Of Lipophilic Pharmaceutical Agents And Methods For Preparing And Using The Same
US Patent:
2012027, Nov 1, 2012
Filed:
Apr 20, 2012
Appl. No.:
13/452033
Inventors:
Borje S. Andersson - Houston TX, US
Benigno C. Valdez - Missouri City TX, US
Jeffrey Tarrand - Houston TX, US
Benigno C. Valdez - Missouri City TX, US
Jeffrey Tarrand - Houston TX, US
International Classification:
A61K 31/255, A61P 31/10, A61P 25/24, A61P 31/12, A61P 25/18, A61K 31/496, A61P 31/04
US Classification:
51425407, 514517
Abstract:
There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.
Azole Pharmaceutical Formulations For Parenteral Administration And Methods For Preparing And Using The Same As Treatment Of Diseases Sensitive To Azole Compounds
US Patent:
2014003, Jan 30, 2014
Filed:
Dec 16, 2011
Appl. No.:
13/994152
Inventors:
Borje S. Andersson - Houston TX, US
Jeffrey Tarrand - Houston TX, US
Benigno C. Valdez - Missouri City TX, US
Jeffrey Tarrand - Houston TX, US
Benigno C. Valdez - Missouri City TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/496, A61K 9/00
US Classification:
51425407
Abstract:
A parenteral azole composition comprises a first solvent, made of benzyl alcohol and/or an acidified alcohol such as ethanol, and a lipophilic component such as PEG400, and the azole, or triazole, such as itraconazole or posaconazole dissolved in this first composite solvent vehicle that is essentially free of surfactants, particularly non-ionic surfactants, and has low levels of water, preferably less than 5% water. The composition may be further diluted with an infusion fluid, such as normal saline or 5% or 10% dextrose in water, before infusion into an immunocompromized mammal, preferably a human. The composition is useful for the treatment and suppression of infections caused by microbes such as yeast and molds that are sensitive to azoles, but it may be extended to dissolve other pharmaceutically active agents that can be used to treat other types of infectious diseases or other ailments, such as malignant and autoimmune diseases.
Modified Reoviral Therapy
US Patent:
7223388, May 29, 2007
Filed:
Aug 2, 2002
Appl. No.:
10/211218
Inventors:
Jeffrey Tarrand - Houston TX, US
Xiang-Yang Han - Bellaire TX, US
Xiang-Yang Han - Bellaire TX, US
Assignee:
Board of Regents, The Univeristy of Texas System - Austin TX
International Classification:
A61K 39/15, A61K 48/00, A61K 47/00, A61K 47/02, A61K 39/00, A61B 5/055
US Classification:
424 931, 424490, 4242151, 4241411, 424 943, 424 9322, 424 9411
Abstract:
The present invention relates to hyperproliferative diseases. Specifically, the present invention encompasses pharmaceutical compositions comprising a modified Reoviridae virus, wherein the Reoviridae virus is conjugated to a hydroxylated hydrocarbon or a polycationic polymer to reduce the clearance of the composition and reduce the immunogenicity of the composition. Yet further, the invention relates to methods of treating a hyperproliferative disease by administering to a patient an effective amount of the modified Reoviridae virus.
Modified Reoviral Therapy
US Patent:
7807179, Oct 5, 2010
Filed:
Apr 27, 2007
Appl. No.:
11/740985
Inventors:
Jeffrey Tarrand - Houston TX, US
Xiang-Yang Han - Bellaire TX, US
Xiang-Yang Han - Bellaire TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 35/00, C12N 7/00
US Classification:
4242151, 424 9411, 424 931
Abstract:
The present invention relates to hyperproliferative diseases. Specifically, the present invention encompasses pharmaceutical compositions comprising a modified Reoviridae virus, wherein the Reoviridae virus is conjugated to a hydroxylated hydrocarbon or a polycationic polymer to reduce the clearance of the composition and reduce the immunogenicity of the composition. Yet further, the invention relates to methods of treating a hyperproliferative disease by administering to a patient an effective amount of the modified Reoviridae virus.
Diagnosis Of Mould Infection
US Patent:
2005000, Jan 13, 2005
Filed:
Apr 22, 2004
Appl. No.:
10/829661
Inventors:
Xiang-Yang Han - Bellaire TX, US
Jeffrey Tarrand - Houston TX, US
Audrey Pham - Houston TX, US
Gregory May - Houston TX, US
Jeffrey Tarrand - Houston TX, US
Audrey Pham - Houston TX, US
Gregory May - Houston TX, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
The present invention provides methods for detecting the presence of pathogenic moulds in biological samples that are based on amplification of mould nucleic acids. The methods may further comprise quantitating and real time detection of the mould. The methods of the invention are highly specific and do not co-amplify human or other yeast nucleic acids. The methods of the invention are also extremely sensitive. Thus, methods for diagnosing infections caused by mould are provided. The invention also provides kits for detection of moulds.
Diagnosis Of Invasive Mold Infection
US Patent:
2005004, Mar 3, 2005
Filed:
Sep 26, 2003
Appl. No.:
10/672300
Inventors:
Xiang-Yang Han - Bellaire TX, US
Jeffrey Tarrand - Houston TX, US
Audrey Pham - Houston TX, US
Gregory May - Houston TX, US
Jeffrey Tarrand - Houston TX, US
Audrey Pham - Houston TX, US
Gregory May - Houston TX, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
The present invention provides methods for detecting the presence of invasive pathogenic molds in biological samples that are based on amplification of mold nucleic acids. The methods may further comprise quantitating and real time detection of the invasive mold. The methods of the invention are highly specific and do not co-amplify human or other yeast nucleic acids. The methods of the invention are also extremely sensitive. Thus, methods for diagnosing infections caused by invasive mold are provided. The invention also provides kits for detection of invasive molds.
Antiseptic Compositions
US Patent:
8512724, Aug 20, 2013
Filed:
Jun 9, 2006
Appl. No.:
11/916972
Inventors:
Jeffrey J. Tarrand - Houston TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
C11D 3/48
US Classification:
424405, 424401, 424404, 510108, 510391
Abstract:
The present invention provides antiseptic compositions that contain DMSO or DMA, an alcohol (e. g. , isopropanol), and/or an additional antiseptic agent such as iodine. In certain embodiments, the antiseptic compositions may be used for skin disinfection and/or skin antisepsis (e. g. , as applied via a swab).